Abstract
The cyclooxygenase-2 (COX-2) enzyme catalyzes the rate-limiting step of prostaglandin formation in pathogenic states. The molecular regulation of COX-2 gene expression is normally tightly regulated on transcriptional and post-transcriptional levels. However, loss of function at either level of COX-2 gene regulation promotes constitutive COX-2 overexpression which plays a key role in carcinogenesis, particularly colorectal tumorigenesis. Current work investigating the regulatory mechanisms of COX-2 expression has demonstrated post-transcriptional regulation to play a central role. Rapid COX-2 mRNA decay and translational inhibition is mediated through a conserved AU-rich element (ARE) present within the 3-untranslated region (3UTR). The COX-2 ARE exerts its control through association with ARE RNA-binding proteins. These trans-acting regulatory factors influence the fate of COX-2 mRNA by controlling mRNA degradation, stabilization, or translation. Recent evidence demonstrates the functional significance rapid mRNA decay and translational inhibition play in controlling COX-2 gene expression and that, if dysregulated, allow for overexpression of COX-2 and other associated angiogenic factors detected in neoplasia.
Keywords: cox, cyclooxygenase, prostaglandins, cancer, post-transcriptional regulation, mrna stability, au-rich element, rna-binding protein
Current Pharmaceutical Design
Title: Dysregulated Post-Transcriptional Control of COX-2 Gene Expression in Cancer
Volume: 10 Issue: 6
Author(s): Dan A. Dixon
Affiliation:
Keywords: cox, cyclooxygenase, prostaglandins, cancer, post-transcriptional regulation, mrna stability, au-rich element, rna-binding protein
Abstract: The cyclooxygenase-2 (COX-2) enzyme catalyzes the rate-limiting step of prostaglandin formation in pathogenic states. The molecular regulation of COX-2 gene expression is normally tightly regulated on transcriptional and post-transcriptional levels. However, loss of function at either level of COX-2 gene regulation promotes constitutive COX-2 overexpression which plays a key role in carcinogenesis, particularly colorectal tumorigenesis. Current work investigating the regulatory mechanisms of COX-2 expression has demonstrated post-transcriptional regulation to play a central role. Rapid COX-2 mRNA decay and translational inhibition is mediated through a conserved AU-rich element (ARE) present within the 3-untranslated region (3UTR). The COX-2 ARE exerts its control through association with ARE RNA-binding proteins. These trans-acting regulatory factors influence the fate of COX-2 mRNA by controlling mRNA degradation, stabilization, or translation. Recent evidence demonstrates the functional significance rapid mRNA decay and translational inhibition play in controlling COX-2 gene expression and that, if dysregulated, allow for overexpression of COX-2 and other associated angiogenic factors detected in neoplasia.
Export Options
About this article
Cite this article as:
Dixon A. Dan, Dysregulated Post-Transcriptional Control of COX-2 Gene Expression in Cancer, Current Pharmaceutical Design 2004; 10 (6) . https://dx.doi.org/10.2174/1381612043453171
DOI https://dx.doi.org/10.2174/1381612043453171 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of miRNAs in Cancer Diagnostics and Therapy: A Recent Update
Current Pharmaceutical Design Rational Drug Design of G-Quartet DNA as Anti-Cancer Agents
Current Pharmaceutical Design Curcumin and Curcumin-like Molecules: From Spice to Drugs
Current Medicinal Chemistry Gabapentin for the Treatment of Cancer-Related Pain Syndromes
Reviews on Recent Clinical Trials The Linkage Between Inflammation and Immune Tolerance: Interfering with Inflammation in Cancer
Current Cancer Drug Targets Inhibition of Anti-Apoptotic Bcl-2 Family Proteins by Natural Polyphenols New Avenues for Cancer Chemoprevention and Chemotherapy
Current Pharmaceutical Design NF-κB1 Intronic Region Polymorphisms as Risk Factor for Head and Neck Cancer in HPV-Infected Population from Pakistan
Current Molecular Medicine Preferentially Expressed Antigen in Melanoma (PRAME) and the PRAME Family of Leucine-Rich Repeat Proteins
Current Cancer Drug Targets Anticancer Potential of Dietary Natural Products: A Comprehensive Review
Anti-Cancer Agents in Medicinal Chemistry The Development of Pro-Apoptotic Cancer Therapeutics
Mini-Reviews in Medicinal Chemistry Drug Design Studies of the Novel Antitumor Targets Carbonic Anhydrase IX and XII
Current Medicinal Chemistry ChemoImmunoModulation: Immune Regulation by the Antineoplastic Chemotherapeutic Agents
Current Medicinal Chemistry Targeting Tumor Suppressor p53 for Cancer Therapy: Strategies, Challenges and Opportunities
Current Drug Targets Reactive Oxygen Species in Cancer Biology and Anticancer Therapy
Current Medicinal Chemistry Dual Roles of Sulforaphane in Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry A Review on Natural Sources Derived Protein Nanoparticles as Anticancer Agents
Current Topics in Medicinal Chemistry Clinical Applications of Gene Therapy in Head and Neck Cancer
Current Gene Therapy EDITORIAL (Hot Topic: “Signal Transduction and Response to Anti-Cancer Therapy”)
Current Signal Transduction Therapy DNA Repair Inhibitors: The Next Major Step to Improve Cancer Therapy
Current Topics in Medicinal Chemistry Of Humans and Hamsters: The Hamster Buccal Pouch Carcinogenesis Model as a Paradigm for Oral Oncogenesis and Chemoprevention
Anti-Cancer Agents in Medicinal Chemistry